Key facts
- This page summarizes Kenneth S. Cragun's Form 4 filing for Alzamend Neuro, Inc. (ALZN).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 Nov 2022, 15:30.
Kenneth S. Cragun - 30 Nov 2022 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)
- Reporting relationship
- SVP of Finance
- Issuer ticker
- ALZN
- Reported as of
- 30 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Nov 2022, 15:30:19 UTC
- Prior SEC filing
- 21 Nov 2022
- Next SEC filing
- 11 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth S. Cragun
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kenneth S. Cragun filed Form 4 for Alzamend Neuro, Inc. (ALZN) on 30 Nov 2022.
Change
- Previous filing in this sequence was filed on 21 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALZN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $1.50
- Footnotes
- F1
ALZN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,500,000
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500,000
- Exercise price
- $1.50
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Mr. Cragun was granted options, exercisable for 10 years, to purchase 1,000,000 shares of the Issuer's common stock, of which (i) 50% would vest if the Issuer's common stock closed at or above $10.00 per share for 90 consecutive trading days, and (ii) 10% would vest for each $2.00 per share increment above $10.00 per share for 90 consecutive trading days, with 100% vesting if the Issuer's common stock closed at or above $20.00 per share for 90 consecutive trading days. After November 27, 2026, the number of any unvested shares subject to the option would decrease by 25%. On November 22, 2022, the Issuer modified the vesting criteria of these options to reduce the price targets, which were previously between $10.00 and $40.00 per share, and to extend the period of time for vesting before the 25% of unvested shares subject to the option would be decreased.
Footnote F2
The stock options vest ratably over 48 months beginning on December 15, 2018.